首页> 外文期刊>Journal of Personalized Medicine >Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics
【24h】

Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

机译:CYP2D6活性评分的十年经验:对未来研究的展望,以改善精确治疗的临床预测

获取原文
           

摘要

The seminal paper on the CYP2D6 Activity Score (AS) was first published ten years ago and, since its introduction in 2008, it has been widely accepted in the field of pharmacogenetics. This scoring system facilitates the translation of highly complex CYP2D6 diplotype data into a patient’s phenotype to guide drug therapy and is at the core of all CYP2D6 gene/drug pair guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The AS, however, only explains a portion of the variability observed among individuals and ethnicities. In this review, we provide an overview of sources in addition to CYP2D6 genotype that contribute to the variability in CYP2D6-mediated drug metabolism and discuss other factors, genetic and non-genetic, that likely contribute to the observed variability in CYP2D6 enzymatic activity.
机译:有关CYP2D6活性评分(AS)的开创性论文于10年前首次发表,自2008年引入以来,已在药物遗传学领域广泛接受。该评分系统有助于将高度复杂的CYP2D6双倍型数据转化为患者的表型,以指导药物治疗,并且是临床药物遗传学实施联盟(CPIC)颁布的所有CYP2D6基因/药物对指南的核心。但是,AS仅解释了个体和种族之间观察到的部分可变性。在本综述中,我们概述了除CYP2D6基因型以外的其他有助于CYP2D6介导的药物代谢变异的来源,并讨论了可能导致所观察到的CYP2D6酶活性变异的其他遗传和非遗传因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号